Literature DB >> 28434650

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy.

Adeera Levin1, Marcello Tonelli2, Joseph Bonventre3, Josef Coresh4, Jo-Ann Donner5, Agnes B Fogo6, Caroline S Fox7, Ron T Gansevoort8, Hiddo J L Heerspink9, Meg Jardine10, Bertram Kasiske11, Anna Köttgen12, Matthias Kretzler13, Andrew S Levey14, Valerie A Luyckx15, Ravindra Mehta16, Orson Moe17, Gregorio Obrador18, Neesh Pannu19, Chirag R Parikh20, Vlado Perkovic21, Carol Pollock22, Peter Stenvinkel23, Katherine R Tuttle24, David C Wheeler25, Kai-Uwe Eckardt26.   

Abstract

The global nephrology community recognises the need for a cohesive plan to address the problem of chronic kidney disease (CKD). In July, 2016, the International Society of Nephrology hosted a CKD summit of more than 85 people with diverse expertise and professional backgrounds from around the globe. The purpose was to identify and prioritise key activities for the next 5-10 years in the domains of clinical care, research, and advocacy and to create an action plan and performance framework based on ten themes: strengthen CKD surveillance; tackle major risk factors for CKD; reduce acute kidney injury-a special risk factor for CKD; enhance understanding of the genetic causes of CKD; establish better diagnostic methods in CKD; improve understanding of the natural course of CKD; assess and implement established treatment options in patients with CKD; improve management of symptoms and complications of CKD; develop novel therapeutic interventions to slow CKD progression and reduce CKD complications; and increase the quantity and quality of clinical trials in CKD. Each group produced a prioritised list of goals, activities, and a set of key deliverable objectives for each of the themes. The intended users of this action plan are clinicians, patients, scientists, industry partners, governments, and advocacy organisations. Implementation of this integrated comprehensive plan will benefit people who are at risk for or affected by CKD worldwide.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28434650     DOI: 10.1016/S0140-6736(17)30788-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  228 in total

Review 1.  The UMOD Locus: Insights into the Pathogenesis and Prognosis of Kidney Disease.

Authors:  Olivier Devuyst; Cristian Pattaro
Journal:  J Am Soc Nephrol       Date:  2017-11-27       Impact factor: 10.121

Review 2.  Regulation of TFEB activity and its potential as a therapeutic target against kidney diseases.

Authors:  Weihuang Zhang; Xiaoyu Li; Shujun Wang; Yanse Chen; Huafeng Liu
Journal:  Cell Death Discov       Date:  2020-05-01

3.  A Rebuttal to "The CKD Classification System in the Precision Medicine Era".

Authors:  Andrew S Levey; Adeera Levin
Journal:  Clin J Am Soc Nephrol       Date:  2017-08-07       Impact factor: 8.237

4.  Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices.

Authors:  Eiichiro Kanda; Naoki Kashihara; Kunihiro Matsushita; Tomoko Usui; Hirokazu Okada; Kunitoshi Iseki; Kenichi Mikami; Tetsuhiro Tanaka; Takashi Wada; Hirotaka Watada; Kohjiro Ueki; Masaomi Nangaku
Journal:  Clin Exp Nephrol       Date:  2018-12       Impact factor: 2.801

5.  Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population.

Authors:  Ray El Boustany; Irina Tasevska; Esther Meijer; Lyanne M Kieneker; Sofia Enhörning; Guillaume Lefèvre; Kamel Mohammedi; Michel Marre; Frédéric Fumeron; Beverley Balkau; Nadine Bouby; Lise Bankir; Stephan Jl Bakker; Ronan Roussel; Olle Melander; Ron T Gansevoort; Gilberto Velho
Journal:  JCI Insight       Date:  2018-07-12

Review 6.  Renal biopsy-driven molecular target identification in glomerular disease.

Authors:  Maja T Lindenmeyer; Matthias Kretzler
Journal:  Pflugers Arch       Date:  2017-06-29       Impact factor: 3.657

7.  Design and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial.

Authors:  Rajiv Agarwal; Andrew E Cramer; Mary Balmes-Fenwick; Arjun D Sinha; Fangqian Ouyang; Wanzhu Tu
Journal:  Am J Nephrol       Date:  2020-07-14       Impact factor: 3.754

8.  Dickkopf-3 (DKK3) in Urine Identifies Patients with Short-Term Risk of eGFR Loss.

Authors:  Stephen Zewinger; Thomas Rauen; Michael Rudnicki; Giuseppina Federico; Martina Wagner; Sarah Triem; Stefan J Schunk; Ioannis Petrakis; David Schmit; Stefan Wagenpfeil; Gunnar H Heine; Gert Mayer; Jürgen Floege; Danilo Fliser; Hermann-Josef Gröne; Thimoteus Speer
Journal:  J Am Soc Nephrol       Date:  2018-10-02       Impact factor: 10.121

9.  The first step in creating national Chronic Kidney Disease (CKD) guidelines - a questionnaire.

Authors:  Vanja Radišić Biljak; Anders Grubb; Isabel Cachapuz Guerra; Etienne Cavalier; Stella Raymondo; Rosa Sierra-Amor; Michele Mussap; Shanthi Naidu Kamathan; Dogan Yucel; Pradip Datta; Takashi Wada; Flavio F Alcantara
Journal:  Biochem Med (Zagreb)       Date:  2019-08-05       Impact factor: 2.313

Review 10.  Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.

Authors:  Radica Z Alicic; Emily J Cox; Joshua J Neumiller; Katherine R Tuttle
Journal:  Nat Rev Nephrol       Date:  2020-11-20       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.